RAPA-201 Cell Therapy for Melanoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new cell therapy called RAPA-201 for individuals with advanced melanoma, a type of skin cancer that has returned or resisted previous treatments involving anti-PD-(L)1 therapy. The trial will determine if this treatment can manage the condition when other options have failed. It suits those whose melanoma cannot be surgically removed and who have not responded to certain cancer therapies. Participants should have undergone frequent treatments without success and still have measurable disease for monitoring. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering hope for those seeking new options.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, you must be at least two weeks from your last cancer treatment, surgery, or participation in other trials.
Is there any evidence suggesting that RAPA-201 is likely to be safe for humans?
Research shows that RAPA-201, a type of cell therapy, is being tested for its safety and effectiveness in treating advanced melanoma, a serious skin cancer. Earlier studies have shown encouraging results. For example, when RAPA-201 was used in other types of solid tumors, it helped control the disease in 60% of patients, and all patients experienced some level of disease control. Importantly, this treatment was safely administered in an outpatient setting, allowing patients to avoid overnight hospital stays.
In another study, RAPA-201 safely managed disease in patients with multiple myeloma, a type of blood cancer, after they underwent treatment to lower their white blood cells. These results suggest that the therapy is generally well-tolerated. However, since this is a phase 2 trial, more research is needed to fully understand the safety of RAPA-201 for patients with melanoma.12345Why do researchers think this study treatment might be promising for melanoma?
Unlike the standard treatments for melanoma, which often include surgery, chemotherapy, or targeted therapies, RAPA-201 is a cell therapy that uses a unique approach. This treatment involves administering a specific dose of RAPA-201 cells directly to the patient. These cells are designed to target and potentially enhance the body's immune response against melanoma cells. Researchers are excited about RAPA-201 because it represents a novel way to harness and amplify the body's natural defenses, offering hope for improved effectiveness and reduced side effects compared to conventional therapies.
What evidence suggests that RAPA-201 might be an effective treatment for melanoma?
Research has shown that RAPA-201 cell therapy, which participants in this trial will receive, could be promising for treating advanced melanoma. In earlier studies, 60% of melanoma patients responded positively to the treatment. Another study found that 64% of patients experienced some level of disease remission, with improvements ranging from partial to complete recovery. These results suggest that RAPA-201 might be effective for patients whose cancer hasn't responded to other treatments. The therapy uses specially designed T-cells, a type of immune cell, to find and attack cancer cells, offering new hope for those with advanced melanoma.13678
Who Is on the Research Team?
Daniel Fowler, M.D.
Principal Investigator
Rapa Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults with advanced melanoma that came back or didn't respond after anti-PD-(L)1 therapy. Participants must have measurable disease, be willing to undergo biopsies, and have recovered from previous treatments. They can't join if they're pregnant, breastfeeding, have an active infection or autoimmune disease, or are currently receiving other cancer therapies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RAPA-201 cell therapy for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Chemotherapy
- RAPA-201
Trial Overview
The study tests RAPA-201 cell therapy in patients who've had melanoma return after PD-(L)1 treatment. It's a phase 2 trial where all participants receive the same treatment without being randomly assigned to different groups.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
RAPA-201 cells will be administered at a target flat dose between 80 and 400 x 10\^6 cells per infusion.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rapa Therapeutics LLC
Lead Sponsor
Citations
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 ...
A group of independent scientists who monitor the safety and scientific integrity of a clinical trial. The DMC can recommend to the sponsor that the trial be ...
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)
In an intent-to-treat (ITT) manner, the efficacy of RAPA-201 cell therapy will be determined by overall response rate (ORR) in metastatic melanoma patients with ...
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)
Initial results on the first RAPA-201 clinical trial in solid tumors (NCT05144698) demonstrated that six out of 10 evaluable melanoma patients (60%) responded ...
RAPA-201 Cell Therapy for Melanoma · Info for Participants
What data supports the effectiveness of the RAPA-201 Cell Therapy treatment for melanoma? The research highlights the potential of using T-cell-based ...
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy ...
Nine of 14 patients (64%) achieved disease remission, with eight partial responses and one stringent complete response. Median progression-free ...
RAPA-201 Therapy of Solid Tumors - NCI
RAPA-201 cells will be administered at a target flat dose of 400 X 10^6 cells per infusion on day 3 of cycles 2 through 6. In the original protocol design, a ...
Rapa's epigenetic reprogramming creates T cell therapies ...
RAPA-201 has safely achieved, exclusively through outpatient therapy, a 60% overall response rate (ORR) and 100% disease control rate in solid tumor patients ...
723 Metabolically reprogrammed autologous Th1/Tc1 cell ...
RAPA-201 safely mediates disease remissions in multiple myeloma when administered after lymphodepleting conditioning.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.